Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative Phase Four announces monopropellant multi-mode propulsion systems Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52
Back To News
Seahorse Bioscience
October 17, 2017

Seahorse Bioscience

Acquired by Agilent Technologies. Developer of tools for measuring cell metabolism.

Cookie Policy Website powered by 100% renewable energy Privacy Policy